Total testosterone and neuropsychiatric symptoms in elderly men with Alzheimer's disease

Texas Alzheimer's Research Care Consortium

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)

Abstract

Abstract Introduction: There has been a significant increase in the use of testosterone in aging men, but little investigation into its impact on men with Alzheimer's disease (AD). The findings of the few studies that have been done are inconsistent. In the present study, we investigated the relationship between total testosterone (TT) and neuropsychiatric symptoms (NPS) in a well-characterized sample of elderly men with mild to moderate AD. Methods: The sample, which was drawn from the Texas Alzheimer's Research Care Consortium Longitudinal Research Cohort, included 87 men who met the criteria for mild to moderate AD. The occurrence of NPS was gathered from caregivers and/or family members with the Neuropsychiatric Inventory. TT was analyzed, and the sample was divided into a low-testosterone group (TT ≤2.5 ng/ml; n = 44) and a borderline/normal group (TT ≥2.6 ng/ml; n = 43). Results: TT was correlated with symptoms of hallucinations, delusions, agitation, irritability and motor activity. The borderline/normal group was significantly more likely to have hallucinations (odds ratio (OR) = 5.56), delusions (OR = 3.87), motor activity (OR = 3.13) and irritability (OR = 2.77) than the low-testosterone group. Health status and apolipoprotein E ε4 status were not significant factors. Conclusions: The findings of the present study have implications for the use of testosterone replacement therapy in men with AD or the prodromal stage of the disease.

Original languageEnglish
Article number107
JournalAlzheimer's Research and Therapy
Volume7
Issue number1
DOIs
StatePublished - 1 Dec 2015

Fingerprint

Testosterone
Alzheimer Disease
Odds Ratio
Delusions
Hallucinations
Motor Activity
Prodromal Symptoms
Apolipoprotein E4
Research
Caregivers
Health Status
Equipment and Supplies

Cite this

@article{7156da85e6194ff6aac1118ebc77aa20,
title = "Total testosterone and neuropsychiatric symptoms in elderly men with Alzheimer's disease",
abstract = "Abstract Introduction: There has been a significant increase in the use of testosterone in aging men, but little investigation into its impact on men with Alzheimer's disease (AD). The findings of the few studies that have been done are inconsistent. In the present study, we investigated the relationship between total testosterone (TT) and neuropsychiatric symptoms (NPS) in a well-characterized sample of elderly men with mild to moderate AD. Methods: The sample, which was drawn from the Texas Alzheimer's Research Care Consortium Longitudinal Research Cohort, included 87 men who met the criteria for mild to moderate AD. The occurrence of NPS was gathered from caregivers and/or family members with the Neuropsychiatric Inventory. TT was analyzed, and the sample was divided into a low-testosterone group (TT ≤2.5 ng/ml; n = 44) and a borderline/normal group (TT ≥2.6 ng/ml; n = 43). Results: TT was correlated with symptoms of hallucinations, delusions, agitation, irritability and motor activity. The borderline/normal group was significantly more likely to have hallucinations (odds ratio (OR) = 5.56), delusions (OR = 3.87), motor activity (OR = 3.13) and irritability (OR = 2.77) than the low-testosterone group. Health status and apolipoprotein E ε4 status were not significant factors. Conclusions: The findings of the present study have implications for the use of testosterone replacement therapy in men with AD or the prodromal stage of the disease.",
author = "{Texas Alzheimer's Research Care Consortium} and James Hall and Wiechmann, {April Rose} and Cunningham, {Rebecca Lynn} and Johnson, {Leigh A.} and Melissa Edwards and Barber, {Robert Clinton} and Meharvan Singh and Scott Winter and Sidney O'Bryant",
year = "2015",
month = "12",
day = "1",
doi = "10.1186/s13195-015-0107-4",
language = "English",
volume = "7",
journal = "Alzheimer's Research and Therapy",
issn = "1758-9193",
publisher = "BioMed Central Ltd.",
number = "1",

}

Total testosterone and neuropsychiatric symptoms in elderly men with Alzheimer's disease. / Texas Alzheimer's Research Care Consortium.

In: Alzheimer's Research and Therapy, Vol. 7, No. 1, 107, 01.12.2015.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Total testosterone and neuropsychiatric symptoms in elderly men with Alzheimer's disease

AU - Texas Alzheimer's Research Care Consortium

AU - Hall, James

AU - Wiechmann, April Rose

AU - Cunningham, Rebecca Lynn

AU - Johnson, Leigh A.

AU - Edwards, Melissa

AU - Barber, Robert Clinton

AU - Singh, Meharvan

AU - Winter, Scott

AU - O'Bryant, Sidney

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Abstract Introduction: There has been a significant increase in the use of testosterone in aging men, but little investigation into its impact on men with Alzheimer's disease (AD). The findings of the few studies that have been done are inconsistent. In the present study, we investigated the relationship between total testosterone (TT) and neuropsychiatric symptoms (NPS) in a well-characterized sample of elderly men with mild to moderate AD. Methods: The sample, which was drawn from the Texas Alzheimer's Research Care Consortium Longitudinal Research Cohort, included 87 men who met the criteria for mild to moderate AD. The occurrence of NPS was gathered from caregivers and/or family members with the Neuropsychiatric Inventory. TT was analyzed, and the sample was divided into a low-testosterone group (TT ≤2.5 ng/ml; n = 44) and a borderline/normal group (TT ≥2.6 ng/ml; n = 43). Results: TT was correlated with symptoms of hallucinations, delusions, agitation, irritability and motor activity. The borderline/normal group was significantly more likely to have hallucinations (odds ratio (OR) = 5.56), delusions (OR = 3.87), motor activity (OR = 3.13) and irritability (OR = 2.77) than the low-testosterone group. Health status and apolipoprotein E ε4 status were not significant factors. Conclusions: The findings of the present study have implications for the use of testosterone replacement therapy in men with AD or the prodromal stage of the disease.

AB - Abstract Introduction: There has been a significant increase in the use of testosterone in aging men, but little investigation into its impact on men with Alzheimer's disease (AD). The findings of the few studies that have been done are inconsistent. In the present study, we investigated the relationship between total testosterone (TT) and neuropsychiatric symptoms (NPS) in a well-characterized sample of elderly men with mild to moderate AD. Methods: The sample, which was drawn from the Texas Alzheimer's Research Care Consortium Longitudinal Research Cohort, included 87 men who met the criteria for mild to moderate AD. The occurrence of NPS was gathered from caregivers and/or family members with the Neuropsychiatric Inventory. TT was analyzed, and the sample was divided into a low-testosterone group (TT ≤2.5 ng/ml; n = 44) and a borderline/normal group (TT ≥2.6 ng/ml; n = 43). Results: TT was correlated with symptoms of hallucinations, delusions, agitation, irritability and motor activity. The borderline/normal group was significantly more likely to have hallucinations (odds ratio (OR) = 5.56), delusions (OR = 3.87), motor activity (OR = 3.13) and irritability (OR = 2.77) than the low-testosterone group. Health status and apolipoprotein E ε4 status were not significant factors. Conclusions: The findings of the present study have implications for the use of testosterone replacement therapy in men with AD or the prodromal stage of the disease.

UR - http://www.scopus.com/inward/record.url?scp=84928610205&partnerID=8YFLogxK

U2 - 10.1186/s13195-015-0107-4

DO - 10.1186/s13195-015-0107-4

M3 - Article

VL - 7

JO - Alzheimer's Research and Therapy

JF - Alzheimer's Research and Therapy

SN - 1758-9193

IS - 1

M1 - 107

ER -